Journal Scans

With phase 3 trial data published, including patient-reported outcomes, oncologists can now fully weigh how to incorporate sacituzumab govitecan into care.

The phase 3 KEYNOTE-756 study tested perioperative pembrolizumab in high-risk ER+/HER2− early breast cancer. Early data show activity, but key questions remain. Early data show activity, but key questions remain.

Data suggest two years of ovarian function suppression may be enough for some premenopausal women with breast cancer. Could more tailored regimens be coming?

The SONIA trial showed similar outcomes with first- or second-line CDK4/6 inhibitors, but it might not be enough to change care for most patients, experts say.

A new study that suggests ovarian suppression reduces the risk of breast cancer recurrence risk can be used to personalize care, one expert writes.

An expert cautions that it’s too early to push the combination of adjuvant ribocicib and endocrine therapy for HR+/HER2- early breast cancer into regular care.

Ten-year follow-up data from a landmark trial suggest a genetic assay could further stratify patients and further reduce treatment, our expert reviewer writes.

DESTINY-Breast02 showed T-DXd prolongs survival. Now, one expert asks if a key to further survival gains might be found in one group of patients from the trial.

Ten-year data on lower dose, shorter duration tamoxifen suggest it’s effective. But with questions remaining, one expert says it’s not ready for routine use.

Our experts review studies on the problem of low-intensity chemo, de novo metastatic HER2-low disease, and chemotherapy for triple negative tumors.

Our experts review three abstracts in ESR1-mutant HR-positive, HER2-negative metastatic breast cancer from the PADA-1, ELAINE-1, and EMERALD trials in the November 2022 Breast Cancer Journal Scan.

Our experts review three abstracts in breast cancer presented at the 2022 ASCO Annual Meeting in the August 2022 Breast Cancer Journal Scan.